Advertisement
Screener

United Therapeutics Corporation (UTHR) Income (Loss) from Equity Method Investments

2.6 / 5 stars · 62/120 Roast Me

United Therapeutics Corporation Income (Loss) from Equity Method Investments

United Therapeutics Corporation (UTHR) reported Income (Loss) from Equity Method Investments of -$72.00 thousand for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-07-25.

Discontinued › Income Statement › Other Income

us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2013-07-25

  • United Therapeutics Corporation income (loss) from equity method investments for the quarter ending 2013-06-30 was -$72.00K.
  • United Therapeutics Corporation income (loss) from equity method investments for the quarter ending 2013-03-31 was -$47.00K.
  • United Therapeutics Corporation income (loss) from equity method investments for the quarter ending 2012-12-31 was -$33.00K.
  • United Therapeutics Corporation income (loss) from equity method investments for the quarter ending 2012-09-30 was -$48.00K.
  • United Therapeutics Corporation income (loss) from equity method investments for fiscal 2012 was -$143.00K.
  • United Therapeutics Corporation income (loss) from equity method investments for fiscal 2011 was -$119.00K.
  • United Therapeutics Corporation income (loss) from equity method investments for fiscal 2010 was -$160.00K.
  • United Therapeutics Corporation income (loss) from equity method investments for fiscal 2009 was -$141.00K.
Period endIncome (Loss) from Equity Method Investments 3 monthIncome (Loss) from Equity Method Investments 6 monthIncome (Loss) from Equity Method Investments 9 monthIncome (Loss) from Equity Method Investments 12 month
2013-06-30-$72.00K
10-Q · filed 2013-07-25
-$119.00K
10-Q · filed 2013-07-25
-$152.00K
derived: sum of 3 quarters · filed 2013-07-25
-$200.00K
derived: sum of 4 quarters · filed 2013-07-25
2013-03-31-$47.00K
10-Q · filed 2013-04-25
-$80.00K
derived: sum of 2 quarters · filed 2013-04-25
-$128.00K
derived: sum of 3 quarters · filed 2013-04-25
-$170.00K
derived: sum of 4 quarters · filed 2013-07-25
2012-12-31-$33.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
-$81.00K
derived: sum of 2 quarters · filed 2013-02-26
-$123.00K
derived: sum of 3 quarters · filed 2013-07-25
-$143.00K
10-K · filed 2013-02-26
2012-09-30-$48.00K
10-Q · filed 2012-11-01
-$90.00K
derived: sum of 2 quarters · filed 2013-07-25
-$110.00K
10-Q · filed 2012-11-01
-$119.00K
derived: sum of 4 quarters · filed 2013-07-25
2012-06-30-$42.00K
10-Q · filed 2013-07-25
-$62.00K
10-Q · filed 2013-07-25
-$71.00K
derived: sum of 3 quarters · filed 2013-07-25
-$114.00K
derived: sum of 4 quarters · filed 2013-07-25
2012-03-31-$20.00K
10-Q · filed 2013-04-25
-$29.00K
derived: sum of 2 quarters · filed 2013-04-25
-$72.00K
derived: sum of 3 quarters · filed 2013-04-25
-$102.00K
derived: sum of 4 quarters · filed 2013-04-25
2011-12-31-$9.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
-$52.00K
derived: sum of 2 quarters · filed 2013-02-26
-$82.00K
derived: sum of 3 quarters · filed 2013-02-26
-$119.00K
10-K · filed 2013-02-26
2011-09-30-$43.00K
10-Q · filed 2012-11-01
-$73.00K
derived: sum of 2 quarters · filed 2012-11-01
-$110.00K
10-Q · filed 2012-11-01
-$140.00K
derived: sum of 4 quarters · filed 2013-02-26
2011-06-30-$30.00K
10-Q · filed 2012-07-26
-$67.00K
10-Q · filed 2012-07-26
-$97.00K
derived: sum of 3 quarters · filed 2013-02-26
-$136.00K
derived: sum of 4 quarters · filed 2013-02-26
2011-03-31-$37.00K
10-Q · filed 2012-04-26
-$67.00K
derived: sum of 2 quarters · filed 2013-02-26
-$106.00K
derived: sum of 3 quarters · filed 2013-02-26
-$150.00K
derived: sum of 4 quarters · filed 2013-02-26
2010-12-31-$30.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
-$69.00K
derived: sum of 2 quarters · filed 2013-02-26
-$113.00K
derived: sum of 3 quarters · filed 2013-02-26
-$160.00K
10-K · filed 2013-02-26
2010-09-30-$39.00K
10-Q · filed 2011-10-27
-$83.00K
derived: sum of 2 quarters · filed 2011-10-27
-$130.00K
10-Q · filed 2011-10-27
-$172.00K
derived: sum of 4 quarters · filed 2012-02-28
2010-06-30-$44.00K
10-Q · filed 2011-07-28
-$91.00K
10-Q · filed 2011-07-28
-$133.00K
derived: sum of 3 quarters · filed 2012-02-28
-$175.00K
derived: sum of 4 quarters · filed 2012-02-28
2010-03-31-$47.00K
10-Q · filed 2011-04-28
-$89.00K
derived: sum of 2 quarters · filed 2012-02-28
-$131.00K
derived: sum of 3 quarters · filed 2012-02-28
-$169.00K
derived: sum of 4 quarters · filed 2012-02-28
2009-12-31-$42.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28
-$84.00K
derived: sum of 2 quarters · filed 2012-02-28
-$122.00K
derived: sum of 3 quarters · filed 2012-02-28
-$141.00K
10-K · filed 2012-02-28
2009-09-30-$42.00K
10-Q · filed 2010-10-28
-$80.00K
derived: sum of 2 quarters · filed 2010-10-28
-$99.00K
10-Q · filed 2010-10-28
2009-06-30-$38.00K
10-Q · filed 2010-07-28
-$57.00K
10-Q · filed 2010-07-28
2008-12-31-$226.00K
10-K · filed 2011-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viatris Inc (VTRS)United States$20.008B-0.00
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17